Menopausal hormone therapy and cardiovascular risk. Where are we now?
Menopausal hormone therapy and cardiovascular risk. Where are we now? Curr Vasc Pharmacol. 2018 Jul 08;: Authors: Anagnostis P, Paschou SA, Katsiki N, Krikidis D, Lambrinoudaki I, Goulis DG Abstract Transition to menopause is associated with an increase in cardiovascular disease (CVD) risk, mainly attributed to lipid and glucose metabolism dysregulation, as well as to body fat redistribution, leading to abdominal obesity. Indeed, epidemiological evidence suggests that both early menopause (EM, defined as age at menopause
Publication date: Available online 12 July 2020Source: Seminars in Cancer BiologyAuthor(s): Bo Ma, Alan Wells, Liang Wei, Junnian Zheng
Publication date: Available online 11 July 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Manasa Veluvolu, Mausam Patel, Ganesh Narayanasamy, Thomas Kim
Publication date: Available online 13 June 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Thejus T. Jayakrishnan, Veli Bakalov, Yazan Samhouri, Rodney E. Wegner, Santhosh Sadashiv
Publication date: Available online 12 July 2020Source: Acta Pharmaceutica Sinica BAuthor(s): Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xiaolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu, Fanghai Han, Junjian Wang
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Dementia | Depression | Drugs & Pharmacology | Eating Disorders & Weight Management | Epidemiology | Heart | Hormonal Therapy | Hormones | Men | Menopause | Obesity | Oral Cancer | Orthopaedics | Osteoporosis | Ovarian Cancer | Ovaries | Study | Thrombosis | Women